A phase IIIb, open-label, multicenter study to evaluate the safety of 1.0mg/kg subcutaneously administered Efalizumab in adults with moderate to severe plaque psoriasis, including those who are receiving concomitant anti-psoriatic therapies or have recently transitioned from systemic therapies 1% effort 6 subjects